This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

Inclusion Criteria:

• Age > 18 years of age
• Patients with histologically or clinically confirmed germ cell tumor.
• Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy.
• Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
• Signed informed consent

Exclusion Criteria:

• Long-term survivors

  • Patients undergoing active chemotherapy
  • Patients who did not complete 1st line chemotherapy.

Patients diagnosed with testicular germ cell tumors TGCT, divided into non-seminomatous germ cell tumors (NSGCT) and seminomas; both of which are treated with a combination of surgery and chemotherapy or radiation depending on stage of disease.